Tisento Therapeutics is a MA-based developer of novel medicines to treat diseases with significant unmet medical needs.
Tisento Therapeutics has raised $81.0M in total funding. The most recent round was Series A. The last funding was announced in July 2023.
Tisento Therapeutics's investors include Venrock, Polaris Partners, Invus, Sanofi Ventures, Cyclerion Therapeutics.
Tisento Therapeutics is headquartered in Cambridge, United States.
Tisento Therapeutics is a MA-based developer of novel medicines to treat diseases with significant unmet medical needs.
Tisento Therapeutics is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Tisento Therapeutics — Funding & Investors." VCBacked, July 31, 2023, https://www.vcbacked.co/company/tisento-therapeutics. Accessed July 19, 2026.
VCBacked. (2023). Tisento Therapeutics — Funding & Investors. Retrieved July 19, 2026, from https://www.vcbacked.co/company/tisento-therapeutics
{{cite web |title=Tisento Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/tisento-therapeutics |website=VCBacked |access-date=July 19, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated